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Abstract
Catheters are the leading source of bloodstream infections for patients in the intensive care unit (ICU).
Comprehensive unit-based programs have proven to be effective in decreasing catheter-related bloodstream
infections (CR-BSIs). ICU rates of CR-BSI higher than 2 per 1,000 catheter-days are no longer acceptable. The locally
adapted list of preventive measures should include skin antisepsis with an alcoholic preparation, maximal barrier
precautions, a strict catheter maintenance policy, and removal of unnecessary catheters. The development of new
technologies capable of further decreasing the now low CR-BSI rate is a major challenge. Recently, new materials
that decrease the risk of skin-to-vein bacterial migration, such as new antiseptic dressings, were extensively tested.
Antimicrobial-coated catheters can prevent CR-BSI but have a theoretical risk of selecting resistant bacteria. An
antimicrobial or antiseptic lock may prevent bacterial migration from the hub to the bloodstream. This review
discusses the available knowledge about these new technologies.
Introduction
Central venous catheters (CVCs) are inserted in
approximately half of all patients in the intensive care
unit (ICU). In Europe, the incidence density of catheter-
related bloodstream infections (CR-BSI) ranges from 1
to 3.1 per 1,000 patient-days [1]. CR-BSIs were asso-
ciated with an attributable mortality of 0% to 11.5% [2]
and an additional stay length of 9-12 days [3,4].
In contrast to other nosocomial infections, CR-BSI has
many device-related risk factors. Consequently, preven-
tion should be possible, provided that rigorous policies
are implemented. Specific education and training of
healthcare workers in CR-BSI prevention and continu-
ous implementation of unit-based quality-improvement
programs are essential. We discuss the potential useful-
ness of new technical developments and put these into
perspective according to available recommendations.
Mechanisms of infection
Colonization of the catheter occurs via two main path-
ways: the extraluminal route and the intraluminal route.
Colonization of short-term CVCs (< 15-20 days) occurs
predominantly from the skin puncture site, whereas
colonization of long-term CVCs is usually related to
intraluminal bacterial spread from a contaminated hub
[5]. In both cases, the source of the micro-organisms is
the patient’s own commensal skin flora. Accordingly, S.
epidermidis is responsible for 40-50% of episodes, fol-
lowed by S. aureus (10-20%). Gram-negative blood-
stream infection, especially Pseudomonas aeruginosa,
Stenotrophomonas sp., and Acinetobacter baumannii, are
recovered in one-third of cases. Candida sp. are recov-
ered in 3-10% of cases.
Biofilm formation on the inner and outer surfaces of
the catheter contributes to the development of CR-BSI.
A biofilm is a complex structure formed by bacteria that
have attached to an artificial surface or dead tissue. Bac-
terial attachment to the catheter surface begins within
24 hours after catheter insertion. The bacteria prolifer-
ate and secrete a polysaccharide matrix, which provides
a medium for the attachment of additional organisms.
Constitution of a biofilm is virtually inevitable but does
not necessarily lead to clinical manifestations of infec-
tion, probably because the bacteria contained in the bio-
film are characterized by slow growth and limited
virulence [6]. Clinical biofilm infection is typically resis-
tant to antimicrobials, not only because the antimicro-
bials cannot penetrate into all the biofilm layers, but
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resistant to immune defence mechanisms.
The pathogenesis of fibrin sheath formation from the
biofilm is poorly understood. According to the best
available evidence, biofilm formation is the first event.
Subsequently, fibrin and many other molecules, such as
laminin, collagen, and even muscle cells, convert the
film to a mature sheath [7]. Metallic cations, such as
magnesium, calcium, and iron, may stabilize the biofilm
and contribute both to its development and bacterial
growth [8]. Catheter thrombosis on the fibrin sheath
may be facilitated by platelet activation, decreased levels
of protein C and antithrombin III, hyperfibrinogenemia,
and homocysteine elevation. Clinical evidence suggests
that the risk of thrombosis may increase with the sever-
ity of the infection, the occurrence of bacteremia, and
CR-BSI [9-11].
Diagnosis of catheter infections
The diagnostic methods that are currently accepted
worldwide must be borne in mind, because differences in
the methods used clearly introduced bias in trials on pre-
ventive strategies. In current French recommendations
for patients with BSI, a positive quantitative [12,13] or
semiquantitative [14] catheter culture is needed to deter-
mine that the catheter caused the BSI. Alternatively,
simultaneous comparative quantitative blood samples
[ 1 5 ]o rt h ed i f f e r e n c ei nt i m e to positivity of blood from
the hub and peripheral blood [16] should be determined.
However, the Centers for Disease Control definition of
central-line associated bloodstream infection (CLABSI)
[17], which does not take catheter culture results into
account, often is used as an acceptable surrogate. This
definition requires a single blood culture positive for a
pathogen (or two cultures positive for a common com-
mensal) not recovered from any nonblood cultures dur-
ing the 3 days preceding and 7 days following. This
definition is insufficiently accurate [18,19]. Considerable
variability occurs among experts [20,21] and hospitals
[18] in the classification of infections as CLABSI or sec-
ondary bacteremia. In addition, this definition is
obviously dependent of the number of blood cultures
performed before introducing new antimicrobials and the
number of nonblood cultures performed to look for an
infectious focus responsible for secondary BSI.
Prevention
A number of published studies have investigated various
measures for decreasing the CR-BSI rate [22]. Some of
them evaluated multimodal programs to improve gen-
eral infection control measures when using catheters,
such as surveillance, education, and quality management
strategies, whereas others tested new biomaterials, anti-
septic dressings, and catheter locks.
It should be stated clearly that new biomaterials
should be tested and incorporated into routine preven-
tion programs only if they have been proven to further
decrease the CR-BSI rate below the value obtained
when all the basic guidelines are implemented. We will
now discuss these basic guidelines before focusing on
the potential benefits of new biomaterials.
Basic guidelines for prevention
Catheter insertion
Sterile barrier precautions and skin antisepsis
Although the usefulness of full barrier precautions out-
side the ICU was challenged recently [23], the standard
of care for CR-BSI prevention must continue to include
the use of sterile gloves, a long-sleeved sterile gown, a
mask, a cap, and a large sterile drape during catheter
insertion [24]. Aqueous alcoholic hand rubs improve
adherence to and tolerance of hand-cleansing rules and
are probably at least as effective as surgical hand wash-
ing [25].
Chlorhexidine solution is superior to aqueous povi-
done iodine (PVI) solution for cutaneous antisepsis [26].
Skin disinfection with 2% alcoholic chlorhexidine signifi-
cantly diminished the number of peripheral vein tips
carrying micro-organisms on their surface compared
with 70% ethanol alone [27]. One prospective cohort
study found no difference in catheter colonization or
CR-BSI between 0.5% alcoholic chlorhexidine and 2%
aqueous chlorhexidine [28]. After skin disinfection, the
decrease in micro-organism counts is slightly greater
when the chlorhexidine concentration is increased [29].
A 2% alcoholic chlorhexidine is now available but is
much more expensive than the 0.5% alcoholic solution,
and convincing evidence that it is superior to the lower
concentration is needed. A 5% povidone-70% ethanol
solution was superior to regular 10% PVI in decreasing
catheter colonization (odds ratio [OR], 0.38; 95% confi-
dence interval [CI], 0.22-0.65) and catheter-related infec-
tions (OR, 0.34; 95% CI, 0.13-0.91) [30]. In none of the
available studies was alcoholic-PVI less effective than
chlorhexidine solutions. However, a single-center rando-
mized trial found a significantly lower rate of catheter
colonization (9.7 vs. 18.3 per 1,000 CVC-days) and a
trend toward a lower rate of CR-BSI (1.4 vs. 3.4 per
1,000 CVC-days; P = 0.09) with a solution containing
0.25% chlorhexidine gluconate, 0.025% benzalkonium
chloride, and 4% benzylic alcohol, compared with 5%
alcoholic-PVI [31].
Because chlorhexidine is not only for catheter inser-
tion but also for hand hygiene, preoperative skin pre-
paration and bathing extensive use may result in
resistance [32]. Octenidine (0.1%) in propranolol isopro-
pyl alcohol compared favourably to ethanol/propranolol
in terms of catheter tip colonization (7.9% vs. 17.8%, P
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compared with chlorhexidine and/or alcoholic-PVI [33].
Catheter insertion site
CVC insertion is required in many critically ill patients.
Selection of the insertion site should be based on both
t h ee a s ea n dt h er i s k so ft h ep r o c e d u r e .T h er i s k s
include infection, thrombosis, and mechanical complica-
tions. Subclavian access is preferred for infection control
purposes, although other factors (potential mechanical
complication, thrombosis, and operator experience)
should be considered [34,35]. The use of femoral cathe-
ters is associated with a higher rate of thrombosis and
should probably be restricted to thin patients [36], in
whom the rates of mechanical complications (i.e., pneu-
mothorax and hemorrhage) are unacceptably high with
other routes. In the ICU, the femoral or internal jugular
vein may need to be used, and it should be kept in
mind that catheter tunnelling decreased the risk of CR-
BSI [37,38].
Ultrasound-guided catheter insertion
Ultrasound guidance has been suggested to decrease
the risks of failed catheter insertion and immediate
complications. When the internal jugular vein is used,
this technique may provide benefits [39], such as
decreased rates of failed insertion and mechanical
complications. In an open-label randomized trial of
900 patients, ultrasound use was associated with
decreases in the CR-BSI rate (10.6% vs. 16%, P < 0.01)
and in the mean number of insertion attempts [40].
When ultrasound equipment is available and the physi-
cian is sufficiently well trained in ultrasonography,
ultrasound-guided insertion should be considered rou-
tinely before considering insertion in the internal jugu-
lar vein. The data on femoral and subclavian insertion
are encouraging but are insufficient to draw definitive
conclusions.
Catheter care: replacement, dressings, and tubings
Repeated catheterization may be unavoidable but
increases the risk of catheter infection [41]. Given this
fact and the results of randomized studies, CVCs that
are functioning in patients with no evidence of local or
systemic complications should not be replaced routinely.
This rule may not apply to Swan-Ganz catheters and
arterial catheters, for which the daily risk of infection
may increase with the duration of catheter maintenance
[42,43]. Physicians and nurses should assess the patient’s
need for an intravascular catheter on a daily basis.
Semipermeable transparent dressings, which are
widely used, allow continuous observation of the skin
insertion site and reduce the risk of extrinsic coloniza-
tion. A gauze dressing is preferred if blood is oozing
from the catheter insertion site. Catheter dressings
should be changed immediately if they become damp,
loosened, or soiled.
The optimal frequency of routine of CVC dressing
changes is unknown. The interval between scheduled
changes can be safely increased to 7 days in the ICU,
provided soiled and loosened dressings are changed
immediately [44].
Tubings should be replaced at least every 72 hours.
However, tubing replacement only every 4 days, instead
of every 2 days, did not increase the rate of CR-BSI [45].
Nevertheless, tubings used to administer blood, blood
products, or lipid emulsions (including propofol infu-
sions) should be replaced within 24 hours [46].
Many needleless intravascular connector valves have
been introduced into clinical practice to minimize the
risk of needlestick injury. After disinfection of the con-
nections, microbial contamination of these systems is
lower compared with three-way stopcocks with caps
[47]. However, in cohort studies, needleless systems
often were still contaminated after the widely used pro-
cedure of alcoholic disinfection for 3-5 sec, which is
clearly inadequate. Moreover, most needleless systems
are opaque, making it impossible to verify that they
were properly flushed. These points explain why needle-
less systems have been repeatedly associated with BSI
outbreaks [48-50]. A large epidemiological study in five
hospitals strongly suggested that these systems increased
the risk of central line-associated infections [51]. How-
ever, new silver-impregnated connectors may decrease
microbial contamination.
Overall, any excessive manipulation of CVCs indepen-
dently increases the risk for CR-BSI and must be
avoided [52].
Impact of continuous quality-improvement programs
A comprehensive unit-based safety program combining
staff education, identification of and learning from defi-
ciencies, assignment of a hospital executive to adopt the
unit, and implementation of teamwork tools are essen-
tial to all general safety programs. It is of course funda-
mental to translate the evidence into practice by
creating a checklist, identifying local barriers to guide-
line implementation, measuring performance, participat-
ing in a global network [53], and ensuring that all
healthcare workers are aware of the evidence. The gen-
eral components of a unit-based safety program for con-
trolling CR-BSIs should be easy to apply.
Practical recommendations for catheter insertion, care,
and surveillance always include three general preventive
measures: prevention and control of multiresistant bac-
teria spread, hand hygiene, and surveillance of nosoco-
mial infections. Specific measures to prevent catheter
infections can be effective only if they are followed scru-
pulously. Healthcare workers should first focus on sev-
eral established methods directed at preventing
contamination of the catheter. Suggested bundles should
rest on available recommendations and be adapted
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are: 1) improve adherence to hand hygiene rules; 2)
insert catheters via the subclavian route whenever possi-
ble; 3) use antiseptic solution containing alcohol; 4)
inspect the insertion site daily; 5) immediately change
loosened, soiled, or moistened catheter dressings; and 6)
immediately remove catheters that are no longer indis-
pensable. These simple recommendations often are vio-
lated in everyday practice if the healthcare workers are
not reminded of them frequently. Recent cross-sectional
surveys still found that they were not routinely followed,
particularly outside of the ICU [54,55].
Strong educational efforts designed to obtain the com-
pliance of all healthcare workers with established proto-
cols must be regularly discussed and updated, and
continuous surveillance of CVC infection rates with
feedback to the staff should be instituted. Importantly,
the effects of these educational programs may be sus-
tained if staff members are involved in designing the
measures included in the program and if all new nurses,
residents, and fellows follow an introductory in-service
training program [56]. Simulation-based learning was
recently found to be more effective than video training
alone to improve residents’ skills [57,58] and led to a
dramatic decrease in the CR-BSI rate when the rate in
the control group was high. In a global safety culture
program within the ICU, the identification of a program
leader also is a key factor for success.
Between 2002 and 2010, these recommendations were
found to be successful in many published studies, most
of which were done in the ICU [20,59-62]. In Michigan,
a comprehensive approach based on a bundle of care
combined with an improvement in the safety culture
and teamwork was associated with a dramatic decrease
in CLABSIs, from 7.7 to 1.4 per 1,000 CVC-days, in 103
ICUs (1,981 ICU months; 375,757 catheter-days) [60],
and this effect was sustained [63]. The intervention was
based on five recommended procedures: improved hand
washing, use of full-barrier precautions during CVC
insertion, skin cleansing with chlorhexidine, avoidance
of the femoral site whenever possible, and removal of
unnecessary catheters. The before-after design (with
potential regression-to-the-mean and Hawthorne
effects), very high baseline CLABSI rate, lack of accuracy
of the CLABSI definition [18,64], absence of an assess-
ment of compliance with the study measures, and
absence of data about the relative importance of the var-
ious components of the intervention are important
weaknesses that prevent this study from demonstrating
a causal relationship between the intervention and the
result. Although we believe that the zero-risk concept is
unrealistic and both dangerous and counterproductive
[65], the implementation of bundles of care (adapted
locally) combined with reinforcement of the safety
culture is the crucial first step toward improving cathe-
ter infection rates.
New materials and prevention strategies
Antiseptic-impregnated dressings Even after careful
disinfection, regrowth of the skin flora occurs consis-
tently under the transparent dressing, due to the migra-
tion of bacteria from the dermis to the epidermis and to
the limited efficacy of antiseptic solutions under the
superficial skin [66]. Chlorhexidine-impregnated dres-
sings prevent micro-organism regrowth in the epider-
mis. In a randomized, multicenter assessor-blind trial,
we allocated 1,636 patients to catheter dressings with or
without chlorhexidine-impregnated sponges. A total of
3,778 arterial and central vein catheters were enrolled
(28,931 catheter-days). The use of chlorhexidine-impreg-
nated dressings decreased the risk of major catheter-
related infections (0.6 vs. 1.4 per 1,000 catheter-days;
hazard ratio [HR], 0.39; P =0 . 0 3 )a n dC R - B S I( 0 . 4v s .
1.3 per 1,000 catheter-days; HR, 0.24; P < 0.001) [44]. In
adults, the rate of contact dermatitis seen with the
chlorhexidine-impregnated sponges was 5.3/1,000 cathe-
ters, but no systemic reactions were recorded. In low-
birth-weight infants (< 1,000 g), chlorhexidine sponges
were associated with a far higher rate of contact derma-
titis of 15.3% and therefore should be avoided [67]. New
chlorhexidine-impregnated gel dressings were developed
recently and have been shown to decrease the cutaneous
microflora to a similar extent as the sponges [68]. The
clinical efficacy of this new dressing in ICU patients is
being tested in a large randomized trial (http://www.
clinicaltrial.govNCT 01189682), in which 1,800 of the
1,960 initially planned patients have already been
enrolled.
Silver-alginate-coated dressings have been tested in
the ICU in neonates who had peripherally inserted cen-
tral catheters (PICCs). In a 3:1 randomized pilot study
involving 100 neonates, the silver-alginate coating was
safe and led only to a change in skin color without con-
tact dermatitis [69]. The rate of PICC-associated BSI
decreased from 17.2% to 12.4%. This encouraging result
warrants a randomized trial with sufficient statistical
power to allow a definitive conclusion.
Antithrombotic prophylaxis Both experimental and
cohort studies [9,70] suggest a close relationship
between catheter thrombosis and infection. Several
thrombus proteins increase the adherence of staphylo-
cocci and Candida spp. to catheters. Thrombus forma-
tion on indwelling intravascular catheters is associated
with CR-BSI. Experimental work has demonstrated that
the formation of a fibrin sheath surrounding the cathe-
ter greatly increases catheter colonization [71]. In rats,
subcutaneous administration of the low-molecular-
weight heparin enoxaparin decreases fibrin sheath for-
mation and the incidence of catheter colonization with
Timsit et al. Annals of Intensive Care 2011, 1:34
http://www.annalsofintensivecare.com/content/1/1/34
Page 4 of 9biofilm-producing S. epidermidis [72]. Recent clinical
trials suggest that heparin may reduce catheter-related
infections. In a randomized, double-blind study in criti-
cally ill children, heparin-bonded catheters decreased
the rates of thrombosis (0% vs. 8%, P = 0.006) and posi-
tive blood cultures (drawn through the catheter; 4% vs.
33%, P < 0.0005) [73]. In a double-blind, randomized,
controlled trial in neonates, heparin (0.5 IU/mL) added
to the total parenteral nutrition preparation decreased
all episodes (relative risk [RR] = 0.57, P = 0.04) and defi-
nite episodes (RR = 0.32, P = 0.06) of catheter-related
sepsis [74]. Bone marrow transplant patients were ran-
domly assigned to 100 U/kg per day of heparin or saline
[ 7 5 ] .T h e yf o u n das i g n i f i c a n td e c r e a s ei nt h eC R - B S I
rate in the heparin-treated group (2.5/1,000 CVC-days
vs. 6.4/1,000 CVC-days), without any adverse effects.
Because most heparin solutions contain preservatives
with antimicrobial activity, it is unclear whether a
decrease in the CR-BSI rate would be due to decreased
thrombus formation or the preservative, or both. The
potential benefits of heparin or heparin-coated catheters
must be balanced against the risk of heparin-induced
thrombocytopenia.
Fibrinolytic solutions may decrease the risk of infec-
tion by decreasing biofilm attachment. In a randomized,
double-blind, controlled trial, 181 hematology patients
with intermediate-term catheters (mean duration, 30
days) were allocated to a catheter lock of 25,000 IU of
urokinase or saline for at least 30 minutes, three times
per week. The urokinase lock reduced major blood-
stream infections (4/82 vs. 13/78) because of an effect
limited to coagulase-negative BSIs (1.2% vs. 14.1%; RR =
0.09; 95% CI, 0.01-0.5) and CVC-related thrombosis
(1.3% vs. 9%; RR = 0.14; 95% CI, 0.02-0.82) [76]. In
long-term dialysis catheters, the urokinase lock
decreased the rate of catheter malfunction (22/110
patients vs. 40/115 patients) and significantly decreased
the risks of catheter-related bacteremia (0.34 vs. 1.37/
1,000 catheter-days; P = 0.02) and bacteremia from any
cause (HR, 0.3; 95% CI, 0.11-0.85; P = 0.02) [77].
Antimicrobial-coated or impregnated catheters The
efficacy of catheters whose outer surface is impregnated
with chlorhexidine and silver sulfadiazine was tested in
many randomized studies in the 1990s. A well-con-
ducted meta-analysis concluded that this technique
reduced the risk of CR-BSI (RR = 0.4; 95% CI, 0.2-0.8)
in patients with short-term CVCs [78]. It was mainly
effective when the median duration of insertion was less
than 7 days (median, 6 (range, 5.2-7.5) days; from 4.1%
to 1.9%; OR, 0.48; 95% CI, 0.25-0.91) compared with the
control catheters (median, 12 (range, 7.8-20) days; from
4.5% to 4.2%; OR, 0.94; 95% CI, 0.58-1.54) [79]. This
technique is cost-saving in settings where the incidence
of CR-BSI complicating short-term CVCs is very high
(more than 3.3 per 1,000 catheter-days) and the average
insertion time is less than 8 days.
New chlorhexidine/sulfadiazine-impregnated catheters
with a long half-life of impregnation at the internal and
external surfaces have now been developed. According
to a recent meta-analysis of five randomized, controlled
trials, this catheter halves the risk of CR-BSI (OR, 0.51;
95% CI, 0.56-1.00) [80]. However, this meta-analysis
unmasked significant heterogeneity across study results,
and the pooled CR-BSI rate in the control groups was
unacceptably high in two studies (7.2% and 14%). When
taking into account only the three studies with accepta-
ble CR-BSI rates, chlorhexidine/silver/sulfadiazine-
impregnated catheters failed to significantly decrease the
CR-BSI rate (impregnated 8/614 vs. control 9/589 cathe-
ters; OR (random effect), 0.852; 95% CI, 0.2-3.6) [81].
Resistance to chlorhexidine-sulfadiazine has not been
demonstrated in clinical studies. However, resistance to
chlorhexidine has been induced in vitro [82]. Rare cases of
anaphylactic reaction to the chlorhexidine component of
this catheter have been reported [41]. Consequently, chlor-
hexidine/silver/sulfadiazine-impregnated catheters should
be reserved for patients who are expected to require the
catheter for less than 8 days and who are admitted to a
unit that has high infection rates despite adherence to
other strategies, such as maximal barrier precautions and
implementation of an educational program. As acceptable
incidence rates are between 1 and 3 CR-BSIs per 1,000
catheter-days, the use of such impregnated catheters is not
standard practice. Catheters impregnated with oligon, sil-
ver zeolite, carbon, and platinum have been tested but
have not been proven effective [80].
Catheters impregnated intraluminally and extralumin-
ally with minocycline-rifampin reduce the risk of CR-
BSI compared with polyurethane catheters and exter-
nally coated chlorhexidine/silver/sulfadiazine-impreg-
nated catheters (OR, 0.23; 95% CI, 0.14-0.4) [83]. The
size of the inhibition zone against a reference S. epider-
midis correlated inversely with the duration of catheter
insertion but was greater than 10 mm for a duration of
60 days [84]. Minocycline/rifampin-impregnated cathe-
ters decreased the risk of CR-BSI compared with con-
trols (five ICU studies; OR, 0.26; 95% CI, 0.15-0.47) [80].
However, despite eight randomized, controlled trials, no
clear conclusion could be drawn regarding the impact of
minocycline/rifampin-impregnated catheters on the
development of antimicrobial resistance or on the selec-
tion of resistant flora. In addition, two recent studies
showed an increased risk of Candida spp. catheter colo-
nization [84,85]. However, a large prospective 7-year fol-
low-up study of 9,200 catheters (more than 500,000
catheter-days) in a tertiary university cancer center
failed to unmask the emergence of bacterial resistance
among staphylococcal species [86].
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pressure, new 5-fluorouracil (5-FU)-coated catheters
were recently developed. The pyrimidine analogue 5-FU
is an antimetabolite drug. In concentrations well below
those used in cancer therap y ,5 - F Uh a sb e e ns h o w nt o
inhibit the growth of gram-positive and gram-negative
bacteria and Candida species. In a single-blind, multi-
center, noninferiority, randomized trial, catheters coated
externally with 5-FU were compared to catheters coated
externally with chlorhexidine-silver-sulfadiazine (CH-
SS). 5-FU-coated catheters compared favorably to CH-
SS-coated catheters in terms of catheter tip colonization
(5-FU-coated, 12/419 vs. CH-SS-coated, 21/398 cathe-
ters; difference, -2.6% with an upper confidence limit of
-0.13%) and CR-BSI (5-FU-coated, 0/65 episodes vs.
CH-SS-coated, 2/71 episodes; difference, -2.8%; 95% CI,
-10% to +3%) [87].
An extended review of the biocidal efficacies of var-
ious antimicrobial coatings was published recently [88].
Antibiotic or antiseptic lock solutions The prophylac-
tic use of systemic antibiotics at the time of catheter
insertion has not been proven effective in reducing the
incidence of CR-BSI and is strongly discouraged.
Anti-infective lock solutions are intended for catheters
that are not used continuously. They are effective in
preventing intraluminal contamination. Theoretically,
these solutions produce anti-infective concentrations
that are sufficient to kill organisms embedded in the
biofilm. However, their role in preventing short-term
CR-BSI in the ICU is limited to catheters that are not
used continuously, such as hemodialysis catheters [41]
or PICCs in neonates. A randomized study in critically
ill neonates showed an 80% reduction in PICC-related
BSI with a vancomycin lock administered for 20 or 60
min twice a day [89]. Prospective screening tests for
colonization or infection with vancomycin-resistant
organisms in exposed infants were negative.
In a recent meta-analysis, antibiotic lock solutions for
long-term hemodialysis catheters prevented one CR-BSI
in one of every four patients (95% CI, 4-5) and reduced
the rate of catheter removal [90]. However, significant
publication bias occurred.
Cationic chelators, such as EDTA (edetic acid) or citrate,
have an anticoagulant activity similar to heparin and have
been found to enhance the activity of antimicrobial drugs
against organisms embedded in the biofilm [8].
Many antimicrobials, such as vancomycin, teicoplanin,
daptomycin, gentamicin, cephalosporins, and minocy-
cline, have been tested for lock therapy, with interesting
results. However, in our opinion, antibiotic-antiseptic
lock solutions for CR-BSI prevention should rely only
on molecules that cannot be used for parenteral admin-
istration in human patients. Uncontrolled trials have
shown that taurolidine, a derivative of the
aminosulphonic acid taurine, reduces the risk of CR-BSI
associated with hemodialysis catheters and long-term
intravenous devices [91,92]. A recent, double-blind, ran-
domized, controlled trial compared interdialytic lock
with taurolidine and citrate (1.35% taurolidine and 4%
citrate) to heparin (5,000 U/mL) started at catheter
insertion in 110 adult hemodialysis patients with tun-
nelled cuffed intravascular catheters. Taurolidine-citrate
solution failed to decrease significantly the risk of CR-
BSI (1.4 vs. 2.4 episodes/1,000 catheter-days, P =0 . 1 )
but increased the risk of dysfunction or thrombosis
requiring thrombolytic treatment [93].
In 407 hemodialysis patients with long-term catheters,
Maki et al. recently found in a randomized, assessor-
blind study that a novel catheter lock solution with anti-
microbial and antithrombotic activity containing 0.24 M
(7.0%) sodium citrate, 0.15% methylene blue, 0.15%
methylparaben, and 0.015% propylparaben (C-MB-P)
compared favorably with heparin in terms of both CR-
BSI (0.24 vs. 0.82 per 1,000 catheter-days; RR = 0.29;
95% CI, 0.12-0.7; P = 0.005) and loss because of patency
failure (0 vs. 4; log-rank, P = 0.04) [94]. The impact of
this new lock needs to be tested in short-term hemodia-
lysis catheters used in the ICU.
Ethanol lock solutions also have been evaluated [92].
In vitro, 2 hours of exposure to 70% ethanol is sufficient
to kill established biofilm of gram-positive bacteria,
gram-negative bacteria, and Candida spp. [95] and can
successfully treat persistent bacteremia related to long-
term intravascular devices [96]. Ethanol is effective in
concentrations greater than 20%, and concentrations
greater than 50% inhibit biofilm formation even if left in
place for only 2 minutes [97]. No interactions with
catheter structure have been reported with concentra-
tions lower than 90%.
A first randomized, controlled trial of daily prophylac-
tic lock solution instillation with a 2-hour dwell time
compared 70% ethanol (34 patients) and heparinized sal-
ine (30 patients) in hematological patients with long-
term catheters. Ethanol was associated with a decrease
in CR-BSIs (9% [6/1,000 catheter-days] vs. 37% [31/
1,000 catheter-days], P = 0.003) [98]. A recent rando-
mized, controlled trial in 379 adult hematology patients
failed to confirm these results (15 minutes daily of 70%
ethanol lock solution, 0.7/1,000 catheter-days vs. con-
trol, 1.17/1,000 catheter-days; P = 0.22) [99]. Flushing
the ethanol lock was associated with facial flushing
(40%), altered taste (40%), and dizziness (50%) and
should be strongly discouraged. A large French rando-
mized, double-blind, controlled trial comparing a 2-min
60% ethanol lock to saline for hemodialysis catheters in
ICU patients is ongoing and has already enrolled 1300
of the 1,560 planned patients (http://www.clinicaltrials.
govNCT00875069).
Timsit et al. Annals of Intensive Care 2011, 1:34
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CR-BSI prevention relies chiefly on simple preventive
measures and a continuous quality-improvement pro-
gram. CR-BSI rates greater than 1 or 2 per 1,000 cathe-
ter-days are no longer acceptable. If the rate remains
high under specific circumstances, or to lower the rate
closer to zero, new devices or materials may help.
Among these, only antiseptic-impregnated catheters and
dressings have been proven effective to date. New materi-
als or processes that prevent biofilm formation and bac-
terial growth are being tested. The efficacy and benefits
of new preventive methods must be confirmed in ICUs
where appropriate basal prevention is already optimal.
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